Clinical trial · no report yet · Phase 1
NCT06049576
Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
- NCT06049576 ↗
- Suspended
- City of Hope Medical Center
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 13 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Combination Nivolumab and Ipilimumab With and Without Camu Camu in First Line Treatment of Metastatic Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Suspended
- Conditions
- Clear Cell Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection; Bone Scan; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Myrciaria dubia Prebiotic Supplement; Nivolumab
- Arms
- Arm 1 (nivolumab and ipilimumab) · Active comparator
- Arm 2 (nivolumab, ipilimumab, camu camu) · Experimental
- Enrollment
- 31
- Primary outcomes
- Abundance of ruminococcus in the stool
- Sponsor
- City of Hope Medical Center with National Cancer Institute (NCI)
- Start
- Oct 6, 2023
- Primary completion
- May 25, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06049576 · updated Oct 8, 2026